Reporter brief
Exploring the Anti-ageing Effects of Metformin in COPD
What happened
Trial registry update: NOT_YET_RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract reports only the study design and objectives but does not provide the actual results, effect sizes, or statistical significance, so no conclusions about metformin's efficacy can be drawn from this material
- The generalisability of any findings is limited to COPD patients with confirmed emphysema and documented rapid FEV1 decline; results would not apply to other populations
- Without reported participant numbers or completion rates, the power and reliability of any findings cannot be assessed
Study design and sample
Rct; Human.
COPD patients with evidence of emphysema (by CT scan or reduced DLCO) who are known to have a rapid decrease in FEV1
- Design
- Rct
- Sample
- —
- Journal
- Fundación Instituto de Investigación Sanitaria de Navarra
- Published
- May 31, 2025
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.